Easier Access to Plasma-Derived Medicines: New Discount Rules for Patients.
This act introduces a phase-in for discounts on plasma-derived products under the manufacturer discount program. This aims to ensure better access to these specialized medicines for patients, especially for those who have incurred high treatment costs.
Key points
Plasma-derived products (derived from human whole blood or plasma) will be subject to new discount rules.
Different discount levels will be introduced based on whether a patient has exceeded their annual out-of-pocket drug threshold.
The changes aim to reduce drug costs for patients enrolled in Medicare Part D.
Expired
Citizen Poll